Pilot Study to Test Whether Amifostine Can Further Protect Salivary Function in Head and Neck Cancer Patients Treated With IMRT
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Salivary function at 6 months and yearly compared to pre-treatment salivary function
Wade Thorstad, M.D.
Washington University Medical Center
United States: Institutional Review Board